Literature DB >> 12670876

Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors.

Lutz Fischer1, Dagmar Szellas, Olof Rådmark, Dieter Steinhilber, Oliver Werz.   

Abstract

Nonredox-type 5-lipoxygenase (5-LO) inhibitors such as ZM230487 or L-739.010 potently suppress leukotriene biosynthesis at low cellular peroxide tone. Here, we show that inhibition of 5-LO product formation by nonredox-type 5-LO inhibitors in human isolated polymorphonuclear leukocytes (PMNL) depends on the activation pathway of 5-LO. Thus, compared with 5-LO product synthesis induced by the Ca2+-mobilizing agent ionophore A23187, cell stress-induced 5-LO product formation involving 5-LO kinase pathways required ~10- to 100-fold higher concentrations of ZM230487 or L-739.010 for comparable 5-LO inhibition. No such differences were observed for the iron ligand-type 5-LO inhibitor BWA4C or the novel-type 5-LO inhibitors hyperforin and 3-O-acetyl-11-keto-boswellic acid. Experiments using purified 5-LO revealed that Ca2+ is no prerequisite for potent enzyme inhibition by ZM230487, and exposure of PMNL to the combination of ionophore and cell stress did not restore potent 5-LO suppression. Intriguingly, a significant difference in the potency of nonredox-type inhibitors (but not of BWA4C) was determined between wild-type 5-LO and the mutant S271A/S663A-5-LO (lacking phosphorylation sites for ERK1/2 and MAPKAPK-2) in HeLa cells. Collectively, our data suggest that compared with Ca2+-mediated 5-LO product formation, enzyme activation involving 5-LO phosphorylation events specifically and strongly alters the susceptibility of 5-LO toward nonredox-type inhibitors in intact cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670876     DOI: 10.1096/fj.02-0815fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  23 in total

1.  Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.

Authors:  B Hofmann; C B Rödl; A S Kahnt; T J Maier; A A Michel; M Hoffmann; O Rau; K Awwad; M Pellowska; M Wurglics; M Wacker; A Zivković; I Fleming; M Schubert-Zsilavecz; H Stark; G Schneider; D Steinhilber
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome.

Authors:  Markus Werner; Paul M Jordan; Erik Romp; Anna Czapka; Zhigang Rao; Christian Kretzer; Andreas Koeberle; Ulrike Garscha; Simona Pace; Hans-Erik Claesson; Charles N Serhan; Oliver Werz; Jana Gerstmeier
Journal:  FASEB J       Date:  2019-02-08       Impact factor: 5.191

3.  5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity.

Authors:  A S Fischer; J Metzner; S D Steinbrink; S Ulrich; C Angioni; G Geisslinger; D Steinhilber; T J Maier
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo.

Authors:  C Pergola; B Jazzar; A Rossi; H Northoff; M Hamburger; L Sautebin; O Werz
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Pharmacophore modeling and virtual screening for novel acidic inhibitors of microsomal prostaglandin E₂ synthase-1 (mPGES-1).

Authors:  Birgit Waltenberger; Katja Wiechmann; Julia Bauer; Patrick Markt; Stefan M Noha; Gerhard Wolber; Judith M Rollinger; Oliver Werz; Daniela Schuster; Hermann Stuppner
Journal:  J Med Chem       Date:  2011-04-20       Impact factor: 7.446

6.  Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

Authors:  Lutz Fischer; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

7.  Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo.

Authors:  Christian Feisst; Carlo Pergola; Marija Rakonjac; Antonietta Rossi; Andreas Koeberle; Gabriele Dodt; Marika Hoffmann; Christina Hoernig; Lutz Fischer; Dieter Steinhilber; Lutz Franke; Gisbert Schneider; Olof Rådmark; Lidia Sautebin; Oliver Werz
Journal:  Cell Mol Life Sci       Date:  2009-07-05       Impact factor: 9.261

8.  Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations.

Authors:  Svenja D Steinbrink; Carlo Pergola; Ulrike Bühring; Sven George; Julia Metzner; Astrid S Fischer; Ann-Kathrin Häfner; Joanna M Wisniewska; Gerd Geisslinger; Oliver Werz; Dieter Steinhilber; Thorsten J Maier
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

9.  The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.

Authors:  L Fischer; M Hornig; C Pergola; N Meindl; L Franke; Y Tanrikulu; G Dodt; G Schneider; D Steinhilber; O Werz
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

10.  Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products.

Authors:  Nathaniel C Gilbert; Jana Gerstmeier; Erin E Schexnaydre; Friedemann Börner; Ulrike Garscha; David B Neau; Oliver Werz; Marcia E Newcomer
Journal:  Nat Chem Biol       Date:  2020-05-11       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.